Cinobufagin	B:C0055767
Modulates	B:C0443264
Human	B:C0086418
Innate	O
Immune	O
Responses	O
and	O
Triggers	B:C0032930
Antibacterial	B:C1516002
Activity	I:C1516002
.	O

The	O
traditional	O
Chinese	B:C0008115
medicine	B:C0013227
Chan	B:C0381424
-	I:C0381424
Su	I:C0381424
is	O
widely	O
used	O
for	O
treatment	B:C0920425
of	I:C0920425
cancer	I:C0920425
and	O
cardiovascular	B:C2243057
diseases	I:C2243057
,	O
but	O
also	O
as	O
a	O
remedy	O
for	O
infections	B:C3714514
such	O
as	O
furunculosis	B:C0016867
,	O
tonsillitis	B:C0040425
and	O
acute	B:C0001344
pharyngitis	I:C0001344
.	O

The	O
clinical	O
use	O
of	O
Chan	B:C0381424
-	I:C0381424
Su	I:C0381424
suggests	O
that	O
it	O
has	O
anti-infective	O
effects	O
,	O
however	O
,	O
the	O
mechanism	O
of	O
action	O
is	O
incompletely	O
understood	O
.	O

In	O
particular	O
,	O
the	O
effect	O
on	O
the	O
human	B:C0086418
immune	B:C0020962
system	I:C0020962
is	O
poorly	O
defined	O
.	O

Here	O
,	O
we	O
describe	O
previously	O
unrecognized	O
immunomodulatory	B:C1963758
activities	O
of	O
cinobufagin	B:C0055767
(	O
cinobufagin	B:C0055767
)	O
,	O
a	O
major	O
bioactive	O
component	O
of	O
Chan	B:C0381424
-	I:C0381424
Su	I:C0381424
.	O

Using	O
human	B:C0086418
monocyte	B:C3891282
-	I:C3891282
derived	I:C3891282
dendritic	B:C0011306
cells	I:C0011306
(	O
dendritic	B:C0011306
cells	I:C0011306
)	O
,	O
we	O
show	O
that	O
LPS	B:C0023810
-	O
induced	O
maturation	O
and	O
production	O
of	O
a	O
number	O
of	O
cytokines	B:C0079189
was	O
potently	O
inhibited	O
by	O
cinobufagin	B:C0055767
,	O
which	O
also	O
had	O
a	O
pro-apoptotic	O
effect	O
,	O
associated	O
with	O
activation	B:C0014429
of	O
caspase	B:C0291573
-	I:C0291573
3	I:C0291573
.	O

Interestingly	O
,	O
cinobufagin	B:C0055767
triggered	O
caspase	B:C0534519
-	I:C0534519
1	I:C0534519
activation	B:C0014429
and	O
significantly	O
enhanced	O
IL	B:C0021753
-	I:C0021753
1	I:C0021753
Î²	I:C0021753
production	O
in	O
LPS	B:C0023810
-	O
stimulated	O
cells	B:C0007634
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
cinobufagin	B:C0055767
upregulates	B:C0041904
gene	B:C0017262
expression	I:C0017262
of	O
the	O
antimicrobial	B:C4084937
peptides	I:C4084937
(	O
antimicrobial	B:C4084937
peptides	I:C4084937
)	O
hBD	B:C0540333
-	I:C0540333
2	I:C0540333
and	O
hBD	B:C2604787
-	I:C2604787
3	I:C2604787
in	O
dendritic	B:C0011306
cells	I:C0011306
,	O
and	O
induces	O
secretion	B:C0036536
of	O
HNP1	B:C0122620
-	O
3	B:C0122160
and	O
hCAP	B:C0108282
-	I:C0108282
18/LL-37	I:C0108282
from	O
neutrophils	B:C0027950
,	O
potentiating	O
neutrophil	B:C0027950
antibacterial	B:C1516002
activity	I:C1516002
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
cinobufagin	B:C0055767
modulates	B:C0443264
the	O
inflammatory	O
phenotype	O
of	O
dendritic	B:C0011306
cells	I:C0011306
in	O
response	O
to	O
LPS	B:C0023810
,	O
and	O
triggers	B:C0032930
an	O
antibacterial	B:C0279516
innate	O
immune	O
response	O
,	O
thus	O
proposing	O
possible	O
mechanisms	O
for	O
the	O
clinical	O
effects	O
of	O
Chan	B:C0381424
-	I:C0381424
Su	I:C0381424
in	O
anti-infective	B:C1141958
therapy	I:C1141958
.	O

